Megumi Kai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Megumi Kai has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Bora Lim
Department of Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA
25 shared publications - Angela Alexander
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
24 shared publications - Naoto T. Ueno
University of Hawaiʻi Cancer Center Inflammatory Breast Cancer Clinic and Research Program, Honolulu, USA
24 shared publications - Rachel M. Layman
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
24 shared publications - Savitri Krishnamurthy
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
24 shared publications - Alexandre Reuben
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
23 shared publications
Latest Publications
- Open Access
Tumor emboli-associated adaptive stress response signatures identify aggressive disease features in inflammatory breast cancer
Inflammatory breast cancer (IBC) is an aggressive breast cancer subtype characterized by tumor emboli, lymphovascular invasion (LVI), and early dissemination. Herein, we establish adaptive stress response (ASR) as a biologic feature linking stress adaptation to tumor emboli survival, lymphatic dissemination, therapeutic response, and disparities. Using a previously defined 226 ASR-related genes, complementary preclinical models of tumor emboli and lymphatic circulating cell clusters, and independent patient cohorts, we identified ASR genes enriched for XIAP-NFκB, oxidative stress response, inflammatory, and immune pathways. CXCL8 emerged as one of the most highly upregulated transcripts in tumor emboli and was shared across both models; however, CXCL8 , IL6 , and PTGS2 were downregulated in lymphatic circulating cell clusters and LVI-positive triple-negative IBC patients, suggesting dynamic remodeling of inflammatory signaling during dissemination. CYP4B1 was associated with ER status, LVI, and therapeutic response across multiple cohorts, implicating metabolic stress adaptation in dissemination. IL6 and PTGS2 were elevated in self-reported Black patients with triple-negative IBC compared to White patients. Pharmacologic inhibition of XIAP-NFκB and oxidative stress pathways suppressed tumor emboli formation. Collectively, these findings identify ASR signaling as a framework linking tumor emboli survival, dissemination, and therapeutic vulnerability in IBC.
Open AccessTumor emboli-associated adaptive stress response signatures identify aggressive disease features in inflammatory breast cancer
Inflammatory breast cancer (IBC) is an aggressive breast cancer subtype characterized by tumor emboli, lymphovascular invasion (LVI), and early dissemination. Herein, we establish adaptive stress response (ASR) as a biologic feature linking stress adaptation to tumor emboli survival, lymphatic dissemination, therapeutic response, and disparities. Using a previously defined 226 ASR-related genes, complementary preclinical models of tumor emboli and lymphatic circulating cell clusters, and independent patient cohorts, we identified ASR genes enriched for XIAP-NFκB, oxidative stress response, inflammatory, and immune pathways. CXCL8 emerged as one of the most highly upregulated transcripts in tumor emboli and was shared across both models; however, CXCL8 , IL6 , and PTGS2 were downregulated in lymphatic circulating cell clusters and LVI-positive triple-negative IBC patients, suggesting dynamic remodeling of inflammatory signaling during dissemination. CYP4B1 was associated with ER status, LVI, and therapeutic response across multiple cohorts, implicating metabolic stress adaptation in dissemination. IL6 and PTGS2 were elevated in self-reported Black patients with triple-negative IBC compared to White patients. Pharmacologic inhibition of XIAP-NFκB and oxidative stress pathways suppressed tumor emboli formation. Collectively, these findings identify ASR signaling as a framework linking tumor emboli survival, dissemination, and therapeutic vulnerability in IBC.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Impact of Postpartum Diagnosis on Survival of Women with Inflammatory Breast Cancer
Table S1 demonstrates OS, PFS, and RFS by receptor subtype
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Impact of Postpartum Diagnosis on Survival of Women with Inflammatory Breast Cancer
Table S1 demonstrates OS, PFS, and RFS by receptor subtype
- Open Access
- 30 April 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (3)
Use of natural language processing to identify patients with inflammatory breast cancer across a health-care system
Early identification and referral of inflammatory breast cancer remains challenging within large health-care systems, limiting access to specialized care. We developed and evaluated an artificial intelligence–driven platform integrating natural language processing (NLP) with electronic health records to systematically identify potential inflammatory breast cancer patients across 5 campuses. Our platform analyzed 8 623 494 clinical notes, implementing a sequential review process: NLP screening followed by human validation and multidisciplinary confirmation. Initial NLP screening achieved 55.4% positive predictive value, improving to 78.4% with human-in-the-loop review. Notably, among 255 confirmed patients with inflammatory breast cancer, our system demonstrated 92.2% sensitivity, identifying 57 patients (22.4%) that traditional surveillance methods missed. Documentation patterns influenced system performance, with combined inflammatory breast cancer and T4d staging mentions showing the highest predictive value (98.2%). This proof-of-concept study demonstrates that lightweight NLP systems with targeted human review can identify rare cancer cases that may otherwise remain siloed within complex health-care networks, ultimately improving access to specialized care resources.
- 30 April 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (3)
Open AccessUse of natural language processing to identify patients with inflammatory breast cancer across a health-care system
Early identification and referral of inflammatory breast cancer remains challenging within large health-care systems, limiting access to specialized care. We developed and evaluated an artificial intelligence–driven platform integrating natural language processing (NLP) with electronic health records to systematically identify potential inflammatory breast cancer patients across 5 campuses. Our platform analyzed 8 623 494 clinical notes, implementing a sequential review process: NLP screening followed by human validation and multidisciplinary confirmation. Initial NLP screening achieved 55.4% positive predictive value, improving to 78.4% with human-in-the-loop review. Notably, among 255 confirmed patients with inflammatory breast cancer, our system demonstrated 92.2% sensitivity, identifying 57 patients (22.4%) that traditional surveillance methods missed. Documentation patterns influenced system performance, with combined inflammatory breast cancer and T4d staging mentions showing the highest predictive value (98.2%). This proof-of-concept study demonstrates that lightweight NLP systems with targeted human review can identify rare cancer cases that may otherwise remain siloed within complex health-care networks, ultimately improving access to specialized care resources.
- 31 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1583-1592
Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score
Background: Susan G. Komen, the Inflammatory Breast Cancer (IBC) Research Foundation, and the Milburn Foundation convened patient advocates, clinicians, and researchers to propose novel quantitative scoring rubrics for IBC diagnosis. In this study, we developed a multi-institutional clinical dataset to test and validate the proposed scoring system. Methods: IBC (N = 988) and non-IBC (N = 332) cases were identified at 2 institutions with dedicated multidisciplinary IBC programs. The non-IBC cohort included consecutive cT4b and cT4c patients. Standard operating procedures (SOPs) were developed for all ambiguous findings and languages. Three different methods were used for the imputation of missing data, resulting in 3 separate datasets. The sensitivity, specificity, and area under the receiver operator characteristic curve (AUC-ROC) were used to assess the discrimination of the proposed scoring rubric. Results: The distribution of “true IBC” cases was 19.7% very likely IBC, 49.1% strong possibility of IBC, 0.4% weak possibility of IBC, 0.1% very unlikely IBC, and 30.7% unknown; corresponding groupings for true non-IBC cases were 0.6% very likely IBC, 51.8% strong possibility of IBC, 9.9% weak possibility of IBC, 2.1% very unlikely IBC, and 35.5% unknown. The AUC-ROC values for missing data imputation methods were similar (0.83-0.84); exploratory score refinement improved the AUC-ROC to 0.88-0.89. Conclusion: Using the largest multi-institutional IBC clinical database to date, the score has been validated and is available for clinical use at https://www.komen.org/ibc-calc to assist health-care providers and their patients in IBC diagnosis. Exploratory score refinement demonstrates the potential to increase specificity; however, any change requires separate validation.
- 31 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1583-1592
Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score
Background: Susan G. Komen, the Inflammatory Breast Cancer (IBC) Research Foundation, and the Milburn Foundation convened patient advocates, clinicians, and researchers to propose novel quantitative scoring rubrics for IBC diagnosis. In this study, we developed a multi-institutional clinical dataset to test and validate the proposed scoring system. Methods: IBC (N = 988) and non-IBC (N = 332) cases were identified at 2 institutions with dedicated multidisciplinary IBC programs. The non-IBC cohort included consecutive cT4b and cT4c patients. Standard operating procedures (SOPs) were developed for all ambiguous findings and languages. Three different methods were used for the imputation of missing data, resulting in 3 separate datasets. The sensitivity, specificity, and area under the receiver operator characteristic curve (AUC-ROC) were used to assess the discrimination of the proposed scoring rubric. Results: The distribution of “true IBC” cases was 19.7% very likely IBC, 49.1% strong possibility of IBC, 0.4% weak possibility of IBC, 0.1% very unlikely IBC, and 30.7% unknown; corresponding groupings for true non-IBC cases were 0.6% very likely IBC, 51.8% strong possibility of IBC, 9.9% weak possibility of IBC, 2.1% very unlikely IBC, and 35.5% unknown. The AUC-ROC values for missing data imputation methods were similar (0.83-0.84); exploratory score refinement improved the AUC-ROC to 0.88-0.89. Conclusion: Using the largest multi-institutional IBC clinical database to date, the score has been validated and is available for clinical use at https://www.komen.org/ibc-calc to assist health-care providers and their patients in IBC diagnosis. Exploratory score refinement demonstrates the potential to increase specificity; however, any change requires separate validation.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 4. Progression-free survival and overall survival stratified by PD-L1 IHC status (n = 32).
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 4. Progression-free survival and overall survival stratified by PD-L1 IHC status (n = 32).
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Table S2. Induction chemotherapy regimen before the maintenance therapy.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Table S2. Induction chemotherapy regimen before the maintenance therapy.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 7. T-cell activation observed as changes in peripheral blood T-cell receptor repertoire after 2 courses of pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 7. T-cell activation observed as changes in peripheral blood T-cell receptor repertoire after 2 courses of pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 1. CONSORT diagram.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 1. CONSORT diagram.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Table S2. Induction chemotherapy regimen before the maintenance therapy.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Table S2. Induction chemotherapy regimen before the maintenance therapy.